Últimas noticias sobre Verastem (NASDAQ:VSTM) Bolsa

Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Verastem Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Neutral rating and announced a price target of $585. MSCI shares closed at $549.33 on Wednesday. <a href="https://www.benzinga.com/quote/MSCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho initiated coverage on MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with an Outperform rating and announced a price target of $12. MannKind shares closed at $4.69 on Wednesday. <a href="https://www.benzinga.com/quote/MNKD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Kelly Shi initiated coverage on Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy rating and announced a price target of $15. Verastem shares closed at $5.28 on Wednesday. <a href="https://www.benzinga.com/quote/VSTM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Tami Zakaria initiated coverage on Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) with a Neutral rating and announces Price Target of $175. Westinghouse Air Brake shares closed at $175.82 on Wednesday. <a href="https://www.benzinga.com/quote/WAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Annabel Samimy initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy rating and announced a price target of $143. Ligand Pharmaceuticals shares closed at $103.85 on Wednesday.  <a href="https://www.benzinga.com/quote/LGND/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LGND stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="642" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-1024x642.png" alt="" class="wp-image-865923" style="width:490px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-1024x642.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-300x188.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-768x482.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Initiation

Analyst Ratings

LGND

MNKD

MSCI

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Jefferies analyst Kelly Shi initiates coverage on Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy rating and announces Price Target of $15.

Price Target

Jefferies Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $15

Mizuho analyst Mara Goldstein maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $9 to $8.

Mizuho Maintains Outperform on Verastem, Lowers Price Target to $8

Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $13 to $14.

Guggenheim Maintains Buy on Verastem, Raises Price Target to $14

HC Wainwright &amp; Co. analyst Sean Lee maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $7 to $10.

HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $10

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $16 to $14.

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14

Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.81) by 25.93 percent. This is a 45.45 percent increase over losses of $(1.10) per share from the same period last year.

Earnings

Earnings Beats

Verastem Q4 Adj $(0.60) Beats $(0.81) Estimate

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/HNRG/earnings">a fourth-quarter sales miss.</a>
Hallador Energy reported quarterly earnings of 7 cents per share which beat the analyst consensus estimate of a loss of 13 cents per share. The company reported quarterly sales of $94.200 million which missed the analyst consensus estimate of $95.450 million.
Hallador Energy shares dipped 6.8% to $10.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares tumbled 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) declined 6.9% to $5.92 in pre-market trading.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares declined 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) fell 4.8% to $42.05 in pre-market trading.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) fell 4.1% to $6.75 in pre-market trading.</li>
<li>Kenon Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEN#NYSE">KEN</a>) fell 3.4% to $34.04 in pre-market trading after gaining 3% on Monday.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) fell 3.3% to $2.32 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1.6% to $234.30 in pre-market trading. Tesla shares fell 4.8% on Monday after Mizuho cut its price target on the stock from $515 to $430. &nbsp;</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

AKBA

RHLD

TSLA

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial results and <a href="https://www.benzinga.com/quote/HROW/earnings">issued 2025 revenue guidance</a>.
Harrow shares jumped 23.1% to $28.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 45.7% to $26.96 in pre-market trading after jumping over 46% on Monday.</li>
<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) rose 30.4% to $0.7985 in pre-market trading. Bon Natural Life shares dipped 57% on Monday after the company announced the pricing of a $12 million offering of 8,333,332 shares at $1.44/share.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) gained 19.2% to $0.4774 in pre-market trading following a 10% surge on Monday.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) gained 17.8% to $1.39 in pre-market trading after jumping 7% on Monday.</li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) gained 15% to $1.46 in pre-market after gaining 4% on Monday.</li>
<li>Key Tronic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) gained 14.2% to $3.05 in pre-market trading.</li>
<li>FinVolution Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) rose 11% to $10.12 following fourth-quarter results.</li>
<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) rose 9.3% to $14.10 in pre-market trading after gaining 3% on Monday.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 6.3% to $4.73 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 40.3% to $0.5250 in pre-market trading.</li>
<li>Bakkt Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) fell 29.4% to $9.05 in pre-market trading after gaining 7% on Monday.</li>
<li>Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) dipped 25.8% to $0.95 in pre-market trading following fourth-quarter results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) declined 24.3% to $0.1280 in pre-market trading.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) fell 24.1% to $0.0802 in pre-market trading after dipping over 6% on Monday.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares tumbled 18.5% to $1.31 in pre-market trading. AirNet Technology shares jumped 98% on Monday after the company announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 13.1% to $0.2469 in pre-market trading. CEL-SCI announced the pricing of $2.56 million best-efforts offering of 16 million shares of common stock.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell 6.8% to $10.70 in today's pre-market trading following a fourth-quarter sales miss.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) fell 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket

B. Riley Securities analyst Kalpit Patel maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $7 to $9.

B. Riley Securities Maintains Buy on Verastem, Raises Price Target to $9

Guggenheim analyst Michael Schmidt reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) from Buy to Buy.

Reiteration

Guggenheim Reiterates Buy on Verastemto Buy

VS-7375 is on track for U.S. IND filing in Q1 2025 with plans for a Phase 1/2a study in mid-2025. Cash position following recent debt and equity financing provides expected runway beyond potential FDA approval and helps to advance early-stage pipeline.
 &nbsp;
 &nbsp;

Verastem Oncology Unveils 2025 Priorities And Upcoming Catalysts For Its Novel Clinical Pipeline;

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. In addition, the Company announced preliminary clinical data from the Phase 1 study being conducted by GenFleet in China.

Verastem Licenses KRAS G12D Inhibitor VS-7375 Early, Reports Phase 1 Data from GenFleet Study

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management LLC (Oberland Capital). In addition, the Company announced a strategic collaboration with IQVIA Inc. (IQVIA) to leverage IQVIA's world-class infrastructure and established commercialization solutions to complement its launch strategy for the investigational combination of avutometinib plus defactinib for the treatment of recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) planned for mid-2025.

Verastem Secures $150M Credit Facility and $7.5M Equity Investment to Advance Cancer Treatments

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and raises the price target from $13 to $16.

RBC Capital Maintains Outperform on Verastem, Raises Price Target to $16

<h3>Gainers</h3>
<ul>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares rose 252.0% to $4.77 during Tuesday's pre-market session. The company's market cap stands at $26.0 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 147.13% to $1.08. The company's market cap stands at $8.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 99.2% to $0.23. The company's market cap stands at $25.1 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares moved upwards by 39.99% to $1.47. The market value of their outstanding shares is at $52.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares moved upwards by 33.51% to $4.9. The company's market cap stands at $218.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 26.19% to $0.56. The market value of their outstanding shares is at $2.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares decreased by 53.4% to $1.09 during Tuesday's pre-market session. The market value of their outstanding shares is at $227.4 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares declined by 33.54% to $2.16. The market value of their outstanding shares is at $21.9 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) stock decreased by 18.56% to $0.61. The company's market cap stands at $63.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 18.21% to $0.37. The market value of their outstanding shares is at $3.0 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 10.65% to $1.93. The market value of their outstanding shares is at $8.0 million. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock fell 9.03% to $5.95. The company's market cap stands at $196.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDMD

COCP

EYEN

LXEO

ONCO

PLRZ

SGMO

SXTC

TLSA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, the FDA accepted for review the New Drug Application under the accelerated approval pathway for Verastem Oncology&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) <a href="https://www.benzinga.com/pressreleases/24/12/b42733460/verastem-oncology-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-avutome" target="_blank" rel="noreferrer noopener">avutometinib</a>.
The company seeks approval of avutometinib in combination with defactinib for adult patients with recurrent low-grade serous ovarian cancer (LGSOC) who received at least one prior systemic therapy and have a KRAS mutation.
The NDA, which was completed in October 2024, has been granted Priority Review with a Prescription Drug User Fee Act action date of June 30, 2025.
In addition, the FDA has stated that it is not currently planning to hold an advisory committee meeting to discuss the application.
The filing was based on a primary Phase 2 RAMP 201 clinical trial analysis.
The <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.verastem.com%2Fnews-releases%2Fnews-release-details%2Fverastem-oncology-presents-positive-updated-ramp-201-data&amp;esheet=54171616&amp;newsitemid=20241230294719&amp;lan=en-US&amp;anchor=results&amp;index=1&amp;md5=a67a2129bd99232dbc3b31eb12f7bb27" target="_blank" rel="noreferrer noopener">results</a> were presented in an oral presentation at the International Gynecologic Cancer Society Annual Global Meeting in October 2024 and demonstrated that the combination of avutometinib plus defactinib resulted in a substantial overall response rate confirmed by a blinded independent central review, with responses that were typically durable, and that the combination was generally well-tolerated in patients with recurrent KRAS mutant LGSOC.
The NDA also includes supportive data from the FRAME Phase 1 trial, the first study conducted with the combination therapy in recurrent LGSOC.
The company is currently enrolling patients with recurrent LGSOC regardless of KRAS mutation status for RAMP 301, an international Phase 3 trial.
The trial will serve as a confirmatory study for the initial indication and has the potential to support an expanded indication regardless of KRAS mutation status.
In May, Verastem Oncology revealed initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel as a first-line treatment for patients with <a href="https://www.benzinga.com/general/biotech/24/05/39006618/whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday" target="_blank" rel="noreferrer noopener">metastatic pancreatic cancer</a>. 
Price Action: VSTM stock is up 26.4% at $4.64 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42740171/comstock-expands-global-reach-with-renewable-fuel-deal-in-pakistan" target="_blank" rel="noreferrer noopener">Comstock Expands Global Reach With Renewable Fuel Deal In Pakistan: Details</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

If approved, avutometinib in combination with defactinib would be the first-ever FDA-approved treatment specifically for adults with recurrent KRAS mutant LGSOC, the company said.
 &nbsp;

Verastem Oncology Says FDA Accepted For Review The NDA Under Accelerated Approval Pathway For Avutometinib In Combination With Defactinib; PDUFA Target Action Date Is June 30, 2025

Mizuho analyst Mara Goldstein maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and raises the price target from $7 to $9.

Mizuho Maintains Outperform on Verastem, Raises Price Target to $9

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

Press Releases

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Comments

Verastem

Noticias

Últimas noticias sobre Verastem (NASDAQ:VSTM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL